💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

Tenax Therapeutics' levosimendan shows encouraging action in preclinical study; shares ahead 93%

Published 03/01/2018, 11:05 AM
© Reuters.  Tenax Therapeutics' levosimendan shows encouraging action in preclinical study; shares ahead 93%
TENX
-
  • Thinly traded nano cap Tenax Therapeutics (TENX +92.7%) is up on a whopping 65x surge in volume in apparent reaction to its announcement of preclinical data on levosimendan. The results were just published in the journal Pulmonary Circulation.
  • The study showed that treatment with levosimendan, a calcium sensitizer, improved cardiac function and myocardial efficiency in rats with right ventricular failure. In addition, chronic administration of levosimendan improved right heart function. The authors believe the results support the potential clinical use of levosimendan to treat right ventricular failure.
  • Levosimendan is approved in over 60 countries ex-U.S. for the treatment of decompensated heart failure. Tenax acquired the North American rights from Phyxius Pharma in 2013.
  • Now read: AveXis 2017 Q4 - Results - Earnings Call Slides


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.